Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon

Key PointsEli Lilly reported a Q1 2024 EPS rise of 66%, beating analyst expectations by 11 cents, but slightly missed revenue expectations, coming in at $8.77 billion, falling short of $8.94 billion consensus estimates.Eli Lilly raised full-year 2024 EPS and full-year revenue guidance by $2 billion.Eli Lilly broke ground on its new $2.5 billion manufacturing facility in Germany, and its Concord, North Carolina facility expects to produce Wegovy shipments by year's end.5 stocks we like better than Eli Lilly ...